CSIMarket Company Name, Ticker, Competitors, else..
 
Virpax Pharmaceuticals Inc   (NASDAQ: VRPX)
Other Ticker:  
 
 
Price: $0.2950 $0.00 -0.539%
Day's High: $0.3048 Week Perf: -2.96 %
Day's Low: $ 0.29 30 Day Perf: -10.61 %
Volume (M): 274 52 Wk High: $ 5.48
Volume (M$): $ 81 52 Wk Avg: $1.54
Open: $0.29 52 Wk Low: $0.28



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 5
 Employees 6
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 0

Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals Inc is a pharmaceutical company that focuses on developing and commercializing novel pain management therapies. The company is dedicated to addressing unmet medical needs and enhancing patient outcomes by providing innovative, safe, and effective pain relief solutions. Virpax Pharmaceuticals employs advanced technologies and methodologies to develop and optimize its proprietary drug candidates. The company's goal is to provide patients with non-addictive alternatives to traditional pain management methods, ultimately improving their quality of life.


   Company Address: 1055 Westlakes Drive Berwyn 19312 PA
   Company Phone Number: 727-4597   Stock Exchange / Ticker: NASDAQ VRPX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY      % 
BMRN      % 
FOLD      % 
RARE      % 
REGN      % 
VRTX      % 
• View Complete Report
   



Business Update

Advancements in Pain Management Virpax Pharmaceuticals Probudur Shows Promise in Swine Model Study Despite Competiti...

Published Mon, Nov 25 2024 12:47 AM UTC

Abstract: Virpax Pharmaceuticals, Inc. has made significant strides in the development of Probudur, a long-acting liposomal bupivacaine formulation. Recent results from a dose range finding study conducted in a minipig model indicate potential for effective pain management. However, these advancements come amidst a challenging financial landscape, as the company reported a...
Business Update

Suggestions1. Virpax Pharmaceuticals Unveils Positive Probudur Study Outcomes Amid Revenue Challenges2. Vir...

Published Sat, Nov 23 2024 2:48 AM UTC

Virpax Pharmaceuticals Announces Encouraging Results for Probudur Amidst Financial Challenges BERWYN, Pa. In a significant step towards advancing its innovative product pipeline, Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced positive outcomes from a Dose Range Finding (DRF) study conducted on Probudur, a long-acting liposomal bupivacaine formulation. This com...
Business Update

Virpax Pharmaceuticals Advances Pain Management Innovation Positive Results from Probudur Dose Range Finding Stu...

Published Fri, Nov 22 2024 1:47 PM UTC

In a significant stride toward innovative pain management solutions, Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX), a corporation dedicated to developing non-addictive therapeutic options for a variety of conditions including pain management, post-traumatic stress disorder (PTSD), and central nervous system (CNS) disorders, has unveiled encouraging findings from a minipig Dose...
Business Update

Virpax Strengthens its Commitment to Pain Management Solutions with Extended Collaboration with U.S. Health Agencies

Published Thu, Nov 21 2024 10:47 PM UTC

In a significant advancement for pain management, Virpax Pharmaceuticals Inc. (Nasdaq: VRPX) has announced the extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), a distinguished entity of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services. This stra...
Business Update

Virpax Pharmaceuticals, Inc. Closes $5.0 Million Public Offering Amid Ongoing Financial Challenges

Published Mon, Nov 18 2024 7:15 AM UTC

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company headquartered in Berwyn, Pennsylvania, has announced the successful closing of a public offering amounting to $5.0 million. The offering included shares of the Company s common stock, with a par value of $0.00001 per share, as well as pre-funded warrants that enable the purchase of additional shares at ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com